Breaking News

Tweet TWEET

Arena Pharma, Celgene, Incyte, Spectrum Pharma, and Geron Under StockCall's Microscope

 Arena Pharma, Celgene, Incyte, Spectrum Pharma, and Geron Under StockCall's
                                  Microscope

PR Newswire

LONDON, April 17, 2013

LONDON, April 17, 2013 /PRNewswire/ --

In 2012, patents on several blockbuster drugs expired, leading to increasing
competition from generic drug manufacturers. Major drug manufacturers are
likely to see more patent expirations in 2013. As generic competition is
expected to continue rising, major drug manufacturers will have to boost their
product pipeline. One way of doing this will be by collaborating with or
acquiring biotechnology companies that have developed or are developing
potential blockbuster drugs. Among the biotechnology companies that major drug
manufacturers can look at are Arena Pharmaceuticals Inc. (NASDAQ: ARNA),
Celgene Corporation (NASDAQ: CELG), Incyte Corporation (NASDAQ: INCY),
Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Geron Corporation (NASDAQ:
GERN). Biotechnology stocks ended mostly higher on Tuesday, tracking gains in
the broad market. StockCall has released full comprehensive research on ARNA,
CELG, INCY, SPPI, and GERN and these free technical analyses can be downloaded
by signing up at

http://www.stockcall.com/technicalanalysis

Shares of Arena Pharmaceuticals Inc. edged higher on Tuesday. The stock
touched an intra-day high of $8.23 before finishing the day 1.99% higher at
$8.20 on volume of 3.10 million. Arena's shares have struggled so far in 2013,
falling more than 9%. The stock has traded sideways over the past one month,
struggling to break through $8.50 resistance level. Shares of ARNA currently
have support at around $8. Free technical analysis on ARNA available by
signing up at

http://www.StockCall.com/ARNA041713.pdf

Shares of Celgene Corporation rose sharply on Tuesday. The stock rose to an
intra-day high of $123 before finishing the day 1.77% higher at $122.50 on
volume of 2.47 million. Celgene's shares are currently trading close to their
52-week high of $124.10. The stock has had an excellent run so far in 2013,
gaining more than 56%. Celgene's shares are also trading above their 50-day
and 200-day moving averages. Register today and access the free research on
CELG at

http://www.StockCall.com/CELG041713.pdf

Incyte Corporation's shares rose yesterday, however, the gains were limited.
The stock closed 0.52% higher at $21.14 on volume of 1.22 million. Incyte's
shares have fallen nearly 6% in the last three sessions. The stock has slipped
below its 50-day moving average as a result of the recent selloff. The stock's
MACD has also slipped below the signal line and the zero-line, which is a
strong bearish signal. It is still up more than 27% so far this year. The free
report on INCY can be downloaded by signing up now at

http://www.StockCall.com/INCY041713.pdf

Shares of Spectrum Pharmaceuticals Inc. gained on Tuesday, reversing some of
the recent losses. The stock closed 1% higher at $7.08 on volume of 647,500
after touching an intra-day high of $7.17. Despite the gains yesterday,
Spectrum's shares are still down more than 3% in the last three trading
sessions. The stock is currently trading well below its 50-day and 200-day
moving averages. Shares of SPPI currently face stiff resistance at around
$7.50. Free report on SPPI can be accessed by registering at

http://www.StockCall.com/SPPI041713.pdf

Geron Corporation's shares fell sharply on Tuesday, extending their losses
from previous trading sessions. The stock closed 1.89% lower at $1.04 on
volume of 655,100, taking its losses in the last three trading sessions to
over 10.30%. The company's shares have struggled so far in 2013, falling more
than 26%. The stock is currently trading close to $1 support level. Register
with StockCall and download the research on GERN for free at

http://www.StockCall.com/GERN041713.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com 

SOURCE StockCall.com

Contact: Contact Person: William T. Knight, Email: info@stockcall.com, Contact
Number: +1(646)396-9857 (9:00 am EST – 01:30 pm EST)